<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04113616</url>
  </required_header>
  <id_info>
    <org_study_id>KRT-232-104</org_study_id>
    <nct_id>NCT04113616</nct_id>
  </id_info>
  <brief_title>An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)</brief_title>
  <official_title>An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kartos Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kartos Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with
      low-dose cytarabine (LDAC) or Decitabine for the treatment of adults with Acute Myeloid
      Leukemia (AML) and AML secondary to myeloproliferative neoplasms (MPN). Participants must be
      relapsed/refractory (having failed prior therapy) and will be assigned to receive KRT+232
      with LDAC or KRT-232 with Decitabine.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 25, 2019</start_date>
  <completion_date type="Anticipated">July 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Number of dose-limiting toxicities (DLTs) of KRT-232 in combination with cytarabine or decitabine</measure>
    <time_frame>28 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Proportion of patients achieving complete remission (CR) or complete remission with partial hematological improvement (CRh) as determined by European LeukemiaNet (ELN) response criteria</measure>
    <time_frame>28 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A: Proportion of patients achieving complete remission (CR) or complete remission with partial hematological improvement (CRh) as determined by European LeukemiaNet (ELN) response criteria</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving a morphologic leukemia-free state (MLFS), or complete remission with incomplete hematology recovery (CRi), or composite complete remission (CRc = CR + CRh), or partial remission (PR)</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <condition>Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)</condition>
  <arm_group>
    <arm_group_label>KRT-232+LDAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KRT-232 will be administered orally, once daily (QD), on Days 1-7 in combination with LDAC administered at 20 mg/m2/day subcutaneously on Days 1-10 in a 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KRT-232(7-Day)+Decitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KRT-232 will be administered orally, once daily (QD), on Days 1-7 in combination with Decitabine administered at 20 mg/m2/day intravenously on Days 1-5 in a 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KRT-232(14-Day)+Decitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KRT-232 will be administered orally, once daily (QD), on Days 1-7 and Days 15-21 (7 days on/7 days off/7 days on/7 days off) in combination with Decitabine administered at 20 mg/m2/day intravenously on Days 1-5 in a 28-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KRT-232</intervention_name>
    <description>KRT-232 is an experimental MDM2 inhibitor anti-cancer drug taken by mouth.</description>
    <arm_group_label>KRT-232(14-Day)+Decitabine</arm_group_label>
    <arm_group_label>KRT-232(7-Day)+Decitabine</arm_group_label>
    <arm_group_label>KRT-232+LDAC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Cytarabine is an anti-cancer chemotherapy drug taken via injection.</description>
    <arm_group_label>KRT-232+LDAC</arm_group_label>
    <other_name>cytosine arabinoside</other_name>
    <other_name>Cytosar-U</other_name>
    <other_name>Depocyt</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Ara-C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>Decitabine is an anti-cancer chemotherapy drug taken via injection.</description>
    <arm_group_label>KRT-232(14-Day)+Decitabine</arm_group_label>
    <arm_group_label>KRT-232(7-Day)+Decitabine</arm_group_label>
    <other_name>Dacogen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Part A: Patients with relapsed or refractory AML, or newly-diagnosed AML secondary to
             MPN

          -  Part B: Patients with AML secondary to MPN or JAK2 mutation positive AML; patients may
             have been treated with 0 to 2 prior lines of therapy for their AML

          -  Adequate hepatic and renal function

          -  Appropriate prior treatment with an FLT3 or IDH1/2 inhibitor where applicable

        Key Exclusion Criteria:

          -  Patients who are TP53 mutation positive

          -  Prior treatment with an MDM2 antagonist therapy

          -  Patients treated with â‰¥ 18 g/m2 of cytarabine within the prior 90 days are not
             eligible to be treated with cytarabine on this study (but may be treated with
             decitabine)

          -  Patients previously treated with decitabine are not eligible to receive decitabine on
             this study (but may be treated with cytarabine)

          -  Patients who have received an allogeneic HSCT within 90 days of enrollment or are
             eligible for an allogeneic HSCT and have a donor (unless transplant is refused)

          -  Active graft-versus-host disease requiring active therapy or who have received
             immunosuppressive therapy for graft-versus-host disease within 1 month prior

          -  Patients with known CNS involvement with AML, acute promyelocytic leukemia (APL), or a
             history of bleeding diathesis

          -  Patients who have had major surgery within 28 days prior

          -  Women who are pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yulia Khalina</last_name>
    <phone>908-656-2799</phone>
    <email>ykhalina@kartosthera.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>John Mei</last_name>
    <phone>650-542-0136</phone>
    <email>jmei@kartosthera.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria de MÃ¡laga</name>
      <address>
        <city>MÃ¡laga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>MÃ¡laga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universidad de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital ClÃ­nico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cardiff University</name>
      <address>
        <city>Cardiff</city>
        <zip>CF10 3AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>October 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2019</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Decitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

